芬太尼或吗啡治疗慢阻肺持续性呼吸困难的多中心随机交叉试验
该多中心双模拟随机交叉试验纳入58例稳定期COPD伴持续性呼吸困难患者,比较透皮芬太尼(12 μg·h-1)、口服吗啡(10 mg每日两次)与安慰剂各2周。结果显示两种阿片类药物在平均及最重呼吸困难评分、睡眠、健康状况等主要和次要终点上均与安慰剂无显著差异,仅呕吐可能存在差异。
要点
- 透皮芬太尼和口服吗啡均未改善COPD持续性呼吸困难。
- 主要终点平均每日呼吸困难NRS评分与安慰剂无显著差异。
- 次要终点包括最重呼吸困难、睡眠、健康状况等亦无显著差异。
核心结论
- 透皮芬太尼与口服吗啡相比安慰剂,均未对COPD持续性呼吸困难产生阳性疗效。
研究设计与样本
- 多中心、交叉、双模拟随机对照试验,比较透皮芬太尼(12 μg·h-1)、吗啡(10 mg口服每日两次)与安慰剂。
- 三个治疗期各2周,含3天洗脱期;共58例受试者完成59次随机,37例完成研究。
- 纳入标准:COPD所致持续性呼吸困难且优化治疗后仍存在、mMRC评分≥3、FEV1<50%预计值且病情稳定。
主要发现
- 主要终点平均每日呼吸困难NRS评分变化在芬太尼、吗啡与安慰剂间无显著差异。
- 最重每日呼吸困难NRS、健康状况(CCQ)、焦虑(HADS-A)、高碳酸血症(毛细血管血气)、掌控感(CRQ-Mastery)及睡眠质量(NRS)均无显著差异。
- 不良反应除呕吐可能存在差异外,其余与安慰剂无显著差异。
关键数值与推荐
- 主要终点为平均每日呼吸困难评分(NRS)的变化。
- 次要终点包括最重每日呼吸困难(NRS)、健康状况(CCQ)、焦虑(HADS-A)、高碳酸血症(毛细血管血气)、掌控感(CRQ-Mastery)和睡眠质量(NRS)。
临床怎么用
- 对于优化治疗后仍存在持续性呼吸困难的COPD患者,不应常规使用透皮芬太尼或口服吗啡改善呼吸困难。
- 临床决策需权衡阿片类药物的潜在不良反应,尤其是呕吐。
局限性
- 研究完成率较低(37/58),主要脱落原因为急性加重(n=13)和副作用(n=7)。
- 样本量较小,可能影响次要终点及不良反应的统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One of the most prevalent and impactful symptoms in COPD is persistent dyspnoea, occurring in the majority of patients with advanced COPD. Opioids, mostly morphine, have been investigated and suggested as treatment in palliative care guidelines. However, in recent years multiple trials on morphine for persistent dyspnoea have shown no clinical benefit, and there are concerns regarding adverse events. Transdermal fentanyl has not yet been investigated for this indication. METHODS: We performed a multicentre, crossover, double-dummy randomised controlled trial, investigating transdermal fentanyl (12 μg·h-1), morphine (10 mg per os twice daily) and placebo, during three treatment periods of 2 weeks (including a 3-day washout period). Patients with persistent dyspnoea despite optimal therapy and modified Medical Research Council dyspnoea scale score ≥3 caused by COPD, forced expiratory volume in 1 s (FEV1) <50% predicted and stable disease were included. The primary end-point was change in mean daily dyspnoea score on a Numeric Rating Scale (NRS). Secondary outcomes were change in worst daily dyspnoea (NRS), health status (Clinical COPD Questionnaire), anxiety (Hospital Anxiety and Depression Scale-Anxiety), hypercapnia (capillary blood gas), mastery (Chronic Respiratory Questionnaire-Mastery) and sleep quality (NRS). RESULTS: Between April 2019 and November 2024, 59 randomisations were performed in 58 participants (mean±sd 69±7 years; 54% female; FEV1 33±10% predicted); 37 participants completed the study. The main reasons for study discontinuation were exacerbations (n=13) and side-effects (n=7). There were no significant differences between both fentanyl and morphine compared to placebo for mean and worst dyspnoea, sleep, health status, mastery, anxiety, hypercapnia or side-effects (except for a possible difference in vomiting). CONCLUSION: This study demonstrated no positive effect of transdermal fentanyl nor oral morphine compared to placebo in the treatment of persistent dyspnoea in COPD.
引用
- van Dijk M, Mooren KJM, van Beurden-Moeskops W, et al. Fentanyl or morphine for persistent dyspnoea in COPD: a multicentre randomised crossover trial. Eur Respir J. 2026. PMID: 42242759. doi:10.1183/13993003.01431-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。